Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas

NCT06557889 is registered in ClinicalTrials.gov with Institut Claudius Regaud as lead sponsor.

NCT NCT06557889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06557889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas
Lead sponsor
Institut Claudius Regaud
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 21, 2024
Completion date
April 30, 2033
Enrollment
86 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of head and neck